A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

June 7, 2028

Study Completion Date

June 7, 2028

Conditions
Alzheimers Disease
Interventions
DRUG

Trontinemab

Participants will receive IV trontinemab.

OTHER

Placebo

Participants will receive IV placebo.

Trial Locations (11)

32162

RECRUITING

Charter Research - Lady Lake/The Villages, The Villages

32789

RECRUITING

Conquest Research, LLC, Winter Park

34470

RECRUITING

Renstar Medical Research, Ocala

92614

RECRUITING

Irvine Center for Clinical Research, Irvine

11413-2016

RECRUITING

Basil Clinical, Laurelton

M3B 2S7

RECRUITING

Toronto Memory Program, Toronto

616-8255

RECRUITING

National Hospital Organization Utano National Hospital, Kyoto

990-0834

RECRUITING

Yamagata Tokusyukai Hospital, Yamagata

BS32 4SY

RECRUITING

Recognition Health Bristol, Bristol

KT16 9AU

RECRUITING

Surrey and Borders NHS Foundation Trust, Chertsey

W1G 8TA

RECRUITING

RE:Cognition Health, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY